Market
Contract partner to be disclosed at the end of 2031 due to confidentiality requirements
Samsung Biologics has signed a 93.4 billion won contract to manufacture drugs for a Europe-based pharmaceutical company.
Samsung Biologics disclosed the single sales and supply contract in a filing with the Data Analysis, Retrieval and Transfer System (DART) on the 2nd.
The contract is valued at 93,478,620,000 won, equivalent to 2.05% of the company’s consolidated revenue of 4.5569 trillion won last year.
The amount was calculated by applying the day’s initial market exchange rate of 1,359.60 won per dollar to the confirmed contract value of $68,754,502.
The contract runs from the 2nd through Dec. 31, 2031. The end date may change by mutual agreement between the two companies.
The contract partner is scheduled to be disclosed on Dec. 31, 2031, for reasons of business confidentiality; that date may also change.
There is no contract deposit or advance payment.
Biobook Team
biobookmedia@biobook.co.kr
ViOL Medical Wins Thai Approval for HIFU Device, Laying Groundwork for Consumables Revenue
SCD Pharm’s glaucoma drug Latast reaches 11% market share, supplied back to originator
Alteogen’s ALT-B4 Infringes Halozyme Patent in Europe; Keytruda SC Sales Banned in 8 Countries
Immunology Drug Developer TrexBio Prices $117 Million IPO
CKD’s third-generation Lee Ju-won becomes second-largest shareholder as new drug R&D faces a test
HLB Makes Fourth Bid for Liver Cancer Drug Approval; Uncertainty Remains Despite Less Severe Inspection Outcome
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
